Get the Stockscreener App
24.12
0.70%
-0.08
Syndax Pharmaceuticals Inc stock is traded at $24.12, with a volume of 8,186.
It is down -0.70% in the last 24 hours and up +16.26% over the past month.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
See More
Previous Close:
$24.20
Open:
$23.91
24h Volume:
8,186
Relative Volume:
0.01
Market Cap:
$2.11B
Revenue:
$172.60M
Net Income/Loss:
$-285.42M
P/E Ratio:
-7.3173
EPS:
-3.2963
Net Cash Flow:
$-323.17M
1W Performance:
+0.13%
1M Performance:
+16.26%
6M Performance:
+53.25%
1Y Performance:
+83.02%
1-Day Range:
$23.89
$24.16
1-Week Range:
$23.60
$25.59
52-Week Range:
$8.58
$25.59
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Name
Syndax Pharmaceuticals Inc
Sector
Industry
Phone
781-419-1400
Address
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
23.89 | 2.13B | 172.60M | -285.42M | -323.17M | -3.2963 |
VRTX
Vertex Pharmaceuticals Inc
|
452.50 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
752.21 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.13 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.41 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.84 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Resumed | H.C. Wainwright | Buy |
| Sep-10-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Aug-05-25 | Reiterated | BTIG Research | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Jun-28-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Oct-25-23 | Initiated | BofA Securities | Buy |
| Oct-11-23 | Initiated | Goldman | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-11-23 | Initiated | Guggenheim | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jan-03-23 | Initiated | JP Morgan | Overweight |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Apr-11-22 | Initiated | H.C. Wainwright | Buy |
| Feb-15-22 | Initiated | Goldman | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-25-21 | Initiated | Citigroup | Buy |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| May-22-20 | Upgrade | Citigroup | Neutral → Buy |
| May-22-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-18-20 | Downgrade | Citigroup | Buy → Neutral |
| May-11-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-08-19 | Reiterated | H.C. Wainwright | Buy |
| Jan-04-19 | Initiated | Robert W. Baird | Outperform |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Mar-16-17 | Initiated | FBR & Co. | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Oct-07-16 | Initiated | Guggenheim | Buy |
| Mar-28-16 | Initiated | Citigroup | Buy |
| Mar-28-16 | Initiated | JMP Securities | Mkt Outperform |
| Mar-28-16 | Initiated | Morgan Stanley | Overweight |
View All
Syndax Pharmaceuticals Inc Stock (SNDX) Latest News
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Emerges as a High-Growth Momentum Pick Using Minervini's Trend Template - ChartMill
Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 12-Month HighWhat's Next? - MarketBeat
Earnings call transcript: Syndax Pharmaceuticals Q4 2025 revenue beats forecast, stock rises - Investing.com Canada
Hedge Fund Bets: Is Syndax Pharmaceuticals Inc stock showing strong momentumMarket Trend Summary & Daily Price Action Insights - baoquankhu1.vn
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Syndax Pharmaceuticals, Inc. $SNDX Shares Sold by Hudson Bay Capital Management LP - MarketBeat
CEO Moves: Can Syndax Pharmaceuticals Inc stock double in the next yearMarket Activity Report & Community Verified Watchlist Alerts - baoquankhu1.vn
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset - The Motley Fool
DAFNA Capital Reduces Syndax Pharmaceuticals Holding in Q4 2025News and Statistics - IndexBox
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish - The Motley Fool
Kynam Capital Sells $8.18M in Syndax Shares, Position Value RisesNews and Statistics - IndexBox
Biotech Shares Surge 72% with $8 Million Transaction, Yet This Is Why a Fund Remains Optimistic - Bitget
Understanding Momentum Shifts in (SNDX) - Stock Traders Daily
Syndax Pharmaceuticals stock hits 52-week high at 25.16 USD By Investing.com - Investing.com Canada
Can Syndax Pharmaceuticals Inc scale operations efficiently2026 News Drivers & Fast Moving Stock Watchlists - baoquankhu1.vn
Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 52-Week HighWhat's Next? - MarketBeat
SNDX SEC FilingsSyndax Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Syndax Pharma: Two Drug Launches Fuel Transformational Growth (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals Q4 2025 earnings preview - MSN
Is It Time To Reassess Syndax Pharmaceuticals (SNDX) After Its 88.5% One Year Surge? - Yahoo Finance
Kingdon Capital Management L.L.C. Purchases 400,000 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Granahan Investment Management LLC Has $6.10 Million Stock Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals, Inc. $SNDX Shares Acquired by Boothbay Fund Management LLC - MarketBeat
Apis Capital Advisors LLC Takes Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Algert Global LLC Cuts Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Assessing Whether Syndax Pharmaceuticals (SNDX) Still Looks Undervalued After Its Recent Strong Run - simplywall.st
Syndax Pharmaceuticals, Inc. $SNDX Position Reduced by Prosight Management LP - MarketBeat
Is Syndax Pharmaceuticals (SNDX) Pricing Reflect Its 81.5% One Year Share Price Gain - simplywall.st
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment - The Motley Fool
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment - The Motley Fool
SNDX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Syndax Pharmaceuticals at Barclays Conference: Strategic Growth Focus - Investing.com
SNDX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Avoiding Lag: Real-Time Signals in (SNDX) Movement - Stock Traders Daily
Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026 - The Globe and Mail
Syndax Pharmaceuticals stock hits 52-week high at $22.91 By Investing.com - Investing.com Canada
JPMorgan Chase & Co. Increases Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $45.00 - MarketBeat
SNDX: JP Morgan Raises Price Target to $45Maintains Overweigh - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 1-Year HighStill a Buy? - MarketBeat
Syndax Pharmaceuticals : SNDX - 24/7 Wall St.
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates - MSN
Wall Street Zen Upgrades Syndax Pharmaceuticals (NASDAQ:SNDX) to Hold - MarketBeat
JPMorgan Reduces PT on Syndax Pharmaceuticals (SNDX) to $33, Maintains “Overweight” Rating - MSN
Syndax Pharmaceuticals’ Earnings Call Highlights Growth Push - TipRanks
Can Syndax Pharmaceuticals Inc. stock maintain growth trajectory2026 Momentum Check & AI Forecasted Stock Moves - Naître et grandir
Syndax Pharmaceuticals, Inc. $SNDX is Knott David M Jr's 7th Largest Position - MarketBeat
Vanguard Group Inc. Buys 104,683 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Market Wrap: Is Syndax Pharmaceuticals Inc. forming a double bottomWeekly Trading Summary & Reliable Entry Point Alerts - baoquankhu1.vn
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Bitget
Syndax Pharmaceuticals reports inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
Syndax Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:SNDX) 2026-03-03 - Seeking Alpha
Syndax Pharmaceuticals Inc Stock (SNDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
3.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):